175 related articles for article (PubMed ID: 26231462)
1. Thrombopoietin-receptor agonists in children with immune thrombocytopenia.
Neunert CE; Grace RF
Lancet; 2015 Oct; 386(10004):1606-9. PubMed ID: 26231462
[No Abstract] [Full Text] [Related]
2. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
González KJ; Zuluaga SO; DaRos CV; Rodríguez PP; Martí AC
Ann Hematol; 2017 Mar; 96(3):507-508. PubMed ID: 27975127
[No Abstract] [Full Text] [Related]
3. Eltrombopag for chronic immune thrombocytopenia.
Milosevic I; Slade E; Drysdale H;
Lancet; 2016 Jan; 387(10016):336. PubMed ID: 26842445
[No Abstract] [Full Text] [Related]
4. Use of Thrombopoietin-Receptor Agonist in CVID-Associated Immune Thrombocytopenia.
Carrabba M; Barcellini W; Fabio G
J Clin Immunol; 2016 Jul; 36(5):434-6. PubMed ID: 27072856
[No Abstract] [Full Text] [Related]
5. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus.
Magnano L; Enríquez H; Esteve J; Cervera R; Espinosa G
J Rheumatol; 2014 Sep; 41(9):1895-6. PubMed ID: 25179983
[No Abstract] [Full Text] [Related]
6. Immune thrombocytopenic purpura--from agony to agonist.
Schwartz RS
N Engl J Med; 2007 Nov; 357(22):2299-301. PubMed ID: 18046034
[No Abstract] [Full Text] [Related]
7. Eltrombopag for chronic immune thrombocytopenia - Authors' reply.
Grainger JD;
Lancet; 2016 Jan; 387(10016):336-337. PubMed ID: 26842444
[No Abstract] [Full Text] [Related]
8. Thrombopoietin receptor agonists in immune thrombocytopenia of less than 6 months duration.
Arumugaswamy A; He S; Quach H; Brotchie J; Grigg A
Intern Med J; 2014 May; 44(5):519-21. PubMed ID: 24816314
[No Abstract] [Full Text] [Related]
9. Eltrombopag in thrombocytopenia.
Zimmer J; Hentges F; Andrès E
N Engl J Med; 2008 Mar; 358(10):1072; author reply 1072-3. PubMed ID: 18326076
[No Abstract] [Full Text] [Related]
10. Eltrombopag--an oral thrombopoietin agonist.
Sharma V; Randhawa H; Sharma A; Aggarwal S
Eur Rev Med Pharmacol Sci; 2012 Jun; 16(6):743-6. PubMed ID: 22913204
[TBL] [Abstract][Full Text] [Related]
11. [Development of thrombopoietin receptor agonists].
Miyakawa Y
Rinsho Ketsueki; 2009 Oct; 50(10):1434-43. PubMed ID: 19915352
[No Abstract] [Full Text] [Related]
12. Thrombopoietin receptor agonists as an emergency treatment for severe newly diagnosed immune thrombocytopenia in children.
Nolla M; Aladjidi N; Leblanc T; Fernandes H; Ducassou S; Fahd M; Barlogis V; Michel M; Blouin P; Jeziorski E; Benadiba J; Pondarre C; Leverger G; Pasquet M
Blood; 2021 Jan; 137(1):138-141. PubMed ID: 33410895
[No Abstract] [Full Text] [Related]
13. Sustaining platelet counts in chronic ITP.
Nurden AT
Lancet; 2011 Jan; 377(9763):358-60. PubMed ID: 20739056
[No Abstract] [Full Text] [Related]
14. What is publication? The case of eltrombopag.
Benham L; Guo L; Turner R
Lancet; 2011 Jan; 377(9763):360-1. PubMed ID: 21277427
[No Abstract] [Full Text] [Related]
15. [Management of refractory ITP with thrombopoietin receptor agonists].
Tomiyama Y
Rinsho Ketsueki; 2011 Aug; 52(8):627-32. PubMed ID: 21897068
[No Abstract] [Full Text] [Related]
16. Effect of thrombopoietin-receptor agonists on a proliferation-inducing ligand (APRIL) plasma levels in patients with immune thrombocytopaenia.
Álvarez Román MT; Fernández Bello I; Arias-Salgado EG; de Paz R; Jiménez Yuste V; Martín Salces M; Butta NV
Br J Clin Pharmacol; 2014 Sep; 78(3):674-6. PubMed ID: 24602175
[No Abstract] [Full Text] [Related]
17. [Development of myelofibrosis during eltrombopag treatment in a patient with immune thrombocytopenia].
Horikoshi A; Tsukuda J; Abe R; Fujiwara N; Ito E; Takaku T
Rinsho Ketsueki; 2016 May; 57(5):638-41. PubMed ID: 27263792
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin-receptor agonist as a treatment of thrombocytopenia associated with systemic lupus erythematosus.
Moreno Martínez MJ; Gallego P; Moreno Ramos MJ
Reumatol Clin; 2016; 12(1):57. PubMed ID: 26024588
[No Abstract] [Full Text] [Related]
19. New therapy options for chronic immune thrombocytopenic purpura: a breath of fresh air. Introduction.
Francesco R
Eur J Haematol Suppl; 2009 Mar; (71):1-2. PubMed ID: 19200300
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of romiplostim in patients with eltrombopag-resistant or -intolerant immune thrombocytopenia.
Tsukamoto S; Nakaseko C; Takeuchi M; Kumagai K; Komatsu T; Tanaka H; Hara S; Koizumi M; Imai H; Yokota A; Takeuchi M; Inokuchi K; Matsuura Y; Aotsuka N; Wakita H
Br J Haematol; 2013 Oct; 163(2):286-9. PubMed ID: 23862773
[No Abstract] [Full Text] [Related]
[Next] [New Search]
